Full Text:   <242>

Summary:  <27>

CLC number: 

On-line Access: 2022-08-12

Received: 2022-03-07

Revision Accepted: 2022-04-21

Crosschecked: 2022-08-12

Cited: 0

Clicked: 342

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Nadezhda KRAKHMAL

https://orcid.org/0000-0002-1909-1681

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2022 Vol.23 No.8 P.617-624

http://doi.org/10.1631/jzus.B2200113


Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features


Author(s):  Sergey VTORUSHIN, Anastasia DULESOVA, Nadezhda KRAKHMAL

Affiliation(s):  Department of Pathology, Siberian State Medical University Ministry of Health of Russia, Tomsk 634050, Russia; more

Corresponding email(s):   krakhmal@mail.ru

Key Words:  Luminal androgen receptor (LAR) subtype, Triple-negative breast cancer (TNBC), Androgen receptor (AR), Prognosis


Share this article to: More |Next Article >>>

Sergey VTORUSHIN, Anastasia DULESOVA, Nadezhda KRAKHMAL. Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features[J]. Journal of Zhejiang University Science B, 2022, 23(8): 617-624.

@article{title="Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features",
author="Sergey VTORUSHIN, Anastasia DULESOVA, Nadezhda KRAKHMAL",
journal="Journal of Zhejiang University Science B",
volume="23",
number="8",
pages="617-624",
year="2022",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2200113"
}

%0 Journal Article
%T Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features
%A Sergey VTORUSHIN
%A Anastasia DULESOVA
%A Nadezhda KRAKHMAL
%J Journal of Zhejiang University SCIENCE B
%V 23
%N 8
%P 617-624
%@ 1673-1581
%D 2022
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2200113

TY - JOUR
T1 - Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features
A1 - Sergey VTORUSHIN
A1 - Anastasia DULESOVA
A1 - Nadezhda KRAKHMAL
J0 - Journal of Zhejiang University Science B
VL - 23
IS - 8
SP - 617
EP - 624
%@ 1673-1581
Y1 - 2022
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2200113


Abstract: 
According to the classification presented by Lehmann BD (2016), triple-negative breast cancer (TNBC) is a heterogeneous group of malignant tumors with four specific subtypes: basal-like (subtype 1 and subtype 2), mesenchymal, and luminal androgen receptor (LAR) subtypes. The basal-like subtypes of carcinomas predominate in this group, accounting for up to 80% of all cases. Despite the significantly lower proportions of mesenchymal and LAR variants in the group of breast carcinomas with a TNBC profile, such tumors are characterized by aggressive biological behavior. To this end, the LAR subtype is of particular interest, since the literature on such tumors presents different and even contradictory data concerning the disease course and prognosis. This review is devoted to the analysis of the relevant literature, reflecting the main results of studies on the molecular properties and clinical features of the disease course of LAR-type TNBC carcinomas.

三阴性乳腺癌的腔内雄激素受体(LAR)亚型:分子、形态和临床特征

摘要:根据Lehmann BD(2016)分类,三阴性乳腺癌(TNBC)是一组异质性恶性肿瘤,存在4种特定的亚型:基底样亚型(亚型1和亚型2)、间充质亚型和腔内雄激素受体(LAR)亚型。基底样亚型癌在TNBC中占主导地位,约占所有病例的80%。虽然在TNBC患者中,间充质亚型和LAR亚型占比显著较低,但此类肿瘤同样具有侵袭性生物学行为。有关LAR亚型的文献研究在患者病程与预后方面存在明显的争议;为此,本文集中关注LAR亚型,通过对相关文献进行分析,重点展示了LAR型TNBC病程中能够体现其分子特性与临床特征的研究结果。

关键词:LAR亚型;三阴性乳腺癌(TNBC);雄激素受体(AR);预后

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Abd El-RehimDM, PinderSE, PaishCE, et al., 2004. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol, 203(2):661-671.

[2]AliAM, AnsariJAK, Abd El-AzizNM, et al., 2017. Triple negative breast cancer: a tale of two decades. Anticancer Agents Med Chem, 17(4):491-499.

[3]AnestisA, ZoiI, PapavassiliouAG, et al., 2020. Androgen receptor in breast cancer—clinical and preclinical research insights. Molecules, 25(2):358.

[4]AsanoY, KashiwagiS, OnodaN, et al., 2016. Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer. Br J Cancer, 114(1):14-20.

[5]AsgharUS, BarrAR, CuttsR, et al., 2017. Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancer. Clin Cancer Res, 23(18):5561-5572.

[6]AstvatsaturyanK, YueY, WaltsAE, et al., 2018. Androgen receptor positive triple negative breast cancer: clinicopathologic, prognostic, and predictive features. PLoS ONE, 13(6):e0197827.

[7]BalkenholMCA, VreulsW, WautersCAP, et al., 2020. Histological subtypes in triple negative breast cancer are associated with specific information on survival. Ann Diagn Pathol, 46:151490.

[8]BarecheY, VenetD, IgnatiadisM, et al., 2018. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol, 29(4):895-902.

[9]BartonVN, ChristensonJL, GordonMA, et al., 2017. Androgen receptor supports an anchorage-independent, cancer stem cell-like population in triple-negative breast cancer. Cancer Res, 77(13):3455-3466.

[10]BhattacharyaR, BanerjeeK, MukherjeeN, et al., 2017. From molecular insight to therapeutic strategy: the holistic approach for treating triple negative breast cancer. Pathol Res Pract, 213(3):177-182.

[11]BhattaraiS, SainiG, GogineniK, et al., 2020. Quadruple-negative breast cancer: novel implications for a new disease. Breast Cancer Res, 22:127.

[12]BonnefoiH, GrelletyT, TredanO, et al., 2016. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol, 27(5):812-818.

[13]BorriF, GranagliaA, 2021. Pathology of triple negative breast cancer. Semin Cancer Biol, 72:136-145.

[14]Bozovic-SpasojevicI, ZardavasD, BrohéeS, et al., 2017. The prognostic role of androgen receptor in patients with early-stage breast cancer: a meta-analysis of clinical and gene expression data. Clin Cancer Res, 23(11):2702-2712.

[15]BursteinMD, TsimelzonA, PoageGM, et al., 2015. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res, 21(7):1688-1698.

[16]CamoraniS, CrescenziE, GramanziniM, et al., 2017. Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers. Sci Rep, 7:46659.

[17]Chalakur-RamireddyNKR, PakalaSB, 2018. Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer. Biosci Rep, 38(1):BSR20171357.

[18]ChoiJE, KangSH, LeeSJ, et al., 2015. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol, 22(1):82-89.

[19]CollinaF, AquinoG, BrognaM, et al., 2019. LncRNA HOTAIR up-regulation is strongly related with lymph nodes metastasis and LAR subtype of Triple Negative Breast Cancer. J Cancer, 10(9):2018-2024.

[20]DieciMV, TsvetkovaV, GriguoloG, et al., 2019. Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: analysis of 263 patients treated with standard therapy for stage I-III disease. Front Oncol, 9:452.

[21]DingYC, SteeleL, WardenC, et al., 2019. Molecular subtypes of triple-negative breast cancer in women of different race and ethnicity. Oncotarget, 10(2):198-208.

[22]EchavarriaI, López-TarruellaS, PicornellA, et al., 2018. Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann’s refined classification. Clin Cancer Res, 24(8):1845-1852.

[23]ElfgenC, VargaZ, ReeveK, et al., 2019. The impact of distinct triple-negative breast cancer subtypes on misdiagnosis and diagnostic delay. Breast Cancer Res Treat, 177:67-75.

[24]GerratanaL, BasileD, BuonoG, et al., 2018. Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype. Cancer Treat Rev, 68:102-110.

[25]GucalpA, TolaneyS, IsakoffSJ, et al., 2013. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res, 19(19):5505-5512.

[26]GuestiniF, McNamaraKM, IshidaT, et al., 2016. Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification. Expert Opin Ther Targets, 20(6):705-720.

[27]HennigsA, RiedelF, GondosA, et al., 2016. Prognosis of breast cancer molecular subtypes in routine clinical care: a large prospective cohort study. BMC Cancer, 16:734.

[28]HillBS, SarnellaA, CapassoD, et al., 2019. Therapeutic potential of a novel αvβ3 antagonist to hamper the aggressiveness of mesenchymal triple negative breast cancer sub-type. Cancers (Basel), 11(2):139.

[29]HonJDC, SinghB, SahinA, et al., 2016. Breast cancer molecular subtypes: from TNBC to QNBC. Am J Cancer Res, 6(9):1864-1872.

[30]HonmaN, OgataH, YamadaA, et al., 2021. Clinicopathological characteristics and prognostic marker of triple-negative breast cancer in older women. Hum Pathol, 111:10-20.

[31]JiaHY, TruicaCI, WangB, et al., 2017. Immunotherapy for triple-negative breast cancer: existing challenges and exciting prospects. Drug Resist Updat, 32:1-15.

[32]JiangYZ, MaD, SuoC, et al., 2019. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell, 35(3):428-440.E5.

[33]KenslerKH, ReganMM, HengYJ, et al., 2019. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98. Breast Cancer Res, 21:30.

[34]KimS, MoonBI, LimW, et al., 2018. Feasibility of classification of triple negative breast cancer by immunohistochemical surrogate markers. Clin Breast Cancer, 18(5):E1123-E1132.

[35]KonoM, FujiiT, LimB, et al., 2017. Androgen receptor function and androgen receptor-targeted therapies in breast cancer: a review. JAMA Oncol, 3(9):1266-1273.

[36]KumarS, BalA, DasA, et al., 2021. Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer. Breast Cancer Res Treat, 187(3):625-633.

[37]le DuF, EckhardtBL, LimB, et al., 2015. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget, 6(15):12890-12908.

[38]LehmannBD, BauerJA, ChenX, et al., 2011. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest, 121(7):2750-2767.

[39]LehmannBD, JovanovićB, ChenX, et al., 2016. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE, 11(6):e0157368.

[40]LiD, LaiWJ, WangQS, et al., 2021. CD151 enrichment in exosomes of luminal androgen receptor breast cancer cell line contributes to cell invasion. Biochimie, 189:65-75.

[41]LiJW, LiN, JiangYZ, et al., 2020. Ultrasonographic appearance of triple-negative invasive breast carcinoma is associated with novel molecular subtypes based on transcriptomic analysis. Ann Transl Med, 8(7):435.

[42]LiSP, LiXY, YangSQ, et al., 2021. Proteomic landscape of exosomes reveals the functional contributions of CD151 in triple-negative breast cancer. Mol Cell Proteomics, 20:100121.

[43]LiuYR, JiangYZ, XuXE, et al., 2016. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. Breast Cancer Res, 18:33.

[44]MarraA, TrapaniD, VialeG, et al., 2020. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ Breast Cancer, 6:54.

[45]NielsenTO, HsuFD, JensenK, et al., 2004. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 10(16):5367-5374.

[46]ParejaF, GeyerFC, MarchiòC, et al., 2016. Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer, 2:16036.

[47]PerouCM, SørlieT, EisenMB, et al., 2000. Molecular portraits of human breast tumours. Nature, 406(6797):747-752.

[48]PietriE, ConteducaV, AndreisD, et al., 2016. Androgen receptor signaling pathways as a target for breast cancer treatment. Endocr Relat Cancer, 23(10):R485-R498.

[49]SantonjaA, Sánchez-MuñozA, LluchA, et al., 2018. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget, 9(41):26406-26416.

[50]TrainaTA, MillerK, YardleyDA, et al., 2015. Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). J Clin Oncol, 33(15 Suppl):1003.

[51]TrainaTA, MillerK, YardleyDA, et al., 2018. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol, 36(9):884-890.

[52]VidulaN, YauC, WolfD, et al., 2019. Androgen receptor gene expression in primary breast cancer. NPJ Breast Cancer, 5:47.

[53]WagenblastE, SotoM, Gutiérrez-ÁngelS, et al., 2015. A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature, 520(7547):358-362.

[54]WangCJ, PanB, ZhuHJ, et al., 2016. Prognostic value of androgen receptor in triple negative breast cancer: a meta-analysis. Oncotarget, 7(29):46482-46491.

[55]XuM, YuanY, YanPJ, et al., 2020. Prognostic significance of androgen receptor expression in triple negative breast cancer: a systematic review and meta-analysis. Clin Breast Cancer, 20(4):E385-E396.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE